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SF-36 questionnaire was administered to patients who
received COS with follitropin alfa (n = 22) or follitropin
beta (n = 21) in a randomized controlled clinical study.
SF-36 scores before and after COS were obtained for each
patient. Results for the eight “dimensions” of the SF-36
were projected using multifactorial analysis to produce a
composite QOL score. Statistical tests were performed to
determine the percentage of relevant information cap-
tured by the multifactorial analysis and hence the quality
of the composite score. The bootstrap technique was used
to generate additional random samples. The Kol-
mogorov–Smirnov test was used to compare the distrib-
utions of the composite scores for the follitropin alfa and
beta groups. RESULTS: The test performed to validate
the composite QOL score gave a value of 0.55 (55% 
of relevant information captured), compared with an
expected score of 0.125 for a random projection of eight
dimensions into one. The distribution of composite scores
for the two groups was signiﬁcantly different after 30 sim-
ulations (p = 0.004), suggesting a difference in the effects
of the two treatments on QOL. A graphical plot of the
results of 5000 simulations showed that the follitropin
beta group had a greater reduction in QOL as a result of
COS compared with the follitropin alfa group. CON-
CLUSIONS: Mathematical modeling conﬁrms a statisti-
cally signiﬁcant difference in QOL effects of the two
r-hFSH preparations in favor of follitropin alfa.
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OBJECTIVE: To develop an instrument to assess male
patient’s and their female partner’s satisfaction with 
the treatment for erectile dysfunction (ED) and assess 
the comprehensiveness, comprehension, acceptability and
clarity of the instrument. METHODS: Four phases were
performed in the questionnaire development; item gener-
ation, face and content validity, cognitive debrieﬁng, cul-
tural and language adaptation. Item generation was based
on literature review, hypothesized characteristics of the
drug and in-depth interviews with patients and their part-
ners. Perceptions and feelings related to the condition 
and their expectations of treatment were examined. Items
were generated simultaneously in English, French, and
German and adapted to each culture. Content and face
validity were assessed by interviews with patients and
partners in 5 countries. Testing of structure and response
scales, cognitive debrieﬁng and veriﬁcation of conceptual
equivalence between languages was assessed. RESULTS:
A total of 55 interviews were conducted to test face and
content validity for patients, partners and experts. The
ﬁnal content areas deemed important included spontane-
ity, quality of erection, quality of ejaculation, sexual plea-
sure, satisfaction with orgasm, conﬁdence, reliability of
treatment, side effect, convenience, overall satisfaction,
conformity to treatment expectations and intentions for
continued use of drug. Cognitive debrieﬁng with patients
and partners found no problems with comprehension.
Results of the debrieﬁng found some words to be prob-
lematic. There were no cultural differences found between
the English, French, or German version. The question-
naire was revised at each phase. The ﬁnal questionnaire
for both the patient and the partner contained 19 ques-
tions. The questionnaire was then translated into 14 
additional languages for use in clinical trials. CONCLU-
SIONS: The TSS is a comprehensive measure of male ED
patients and their respective partners. Further work is
needed to validate the TSS, identify the domains, test the
responsiveness and determine the appropriate scoring.
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Erectile dysfunction has an impact on Health Related
Quality of Life. It can be expected that it also has some
impact on psychological well-being-related variables,
such as self-conﬁdence and self-esteem. It is, therefore,
worthwhile making available in different languages vali-
dated versions of instruments able to measure these 
parameters. OBJECTIVE: To perform the linguistic 
and psychometric validation of a cultural adaptation to
Spanish of the Johnson and McCoy’s Self-Conﬁdence
Scale to be used in patients with erectile dysfunction (ED).
METHODS: After conducting a linguistic validation of
the scale through two forward translations, backward
translation, and cognitive debrieﬁng interviews the ﬁnal
reconciled version of the scale was to be administered to
200 male patients with ED and 200 male subjects without
ED. Participants were screened for ED by general practi-
tioners and further reviewed by urologists. In addition to
the self-conﬁdence scale, all participants were asked to
answer the Rosenberg’s self-esteem scale. RESULTS: A
total of 387 subjects completed the self-conﬁdence ques-
tionnaire. It showed a high internal consistency (Cron-
bach’s alpha = 0.82), similar to the original English
version (Cronbach’s alpha = 0.84). All items showed a
high correlation with the scale. The correlation of the
scale with self-esteem score was adequate (r = 0.60). A
factorial structure of 5 dimensions was observed in the
Spanish version of the self-conﬁdence scale comparable
to the original structure. Self-conﬁdence scores were
